Krazati (adagrasib)

News alerts, weekly reports and conference planners

Company:

BMS, ZAI Lab

Drug class:

KRAS G12C inhibitor

Related drugs:

KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	adagrasib Sensitive: A1 - Approval adagrasib Sensitive : A1	adagrasib Sensitive: A1 - Approval adagrasib Sensitive : A1
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	adagrasib Sensitive: A1 - Approval adagrasib Sensitive : A1	adagrasib Sensitive: A1 - Approval adagrasib Sensitive : A1
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	cetuximab + adagrasib Sensitive: A1 - Approval cetuximab + adagrasib Sensitive : A1	cetuximab + adagrasib Sensitive: A1 - Approval cetuximab + adagrasib Sensitive : A1
KRAS G12C	Pancreatic Adenocarcinoma	KRAS G12C	Pancreatic Adenocarcinoma	adagrasib Sensitive: A2 - Guideline adagrasib Sensitive : A2	adagrasib Sensitive: A2 - Guideline adagrasib Sensitive : A2
KRAS G12C	Rectal Cancer	KRAS G12C	Rectal Cancer	panitumumab + adagrasib Sensitive: A2 - Guideline panitumumab + adagrasib Sensitive : A2	panitumumab + adagrasib Sensitive: A2 - Guideline panitumumab + adagrasib Sensitive : A2
KRAS G12C	Rectal Cancer	KRAS G12C	Rectal Cancer	cetuximab + adagrasib Sensitive: A2 - Guideline cetuximab + adagrasib Sensitive : A2	cetuximab + adagrasib Sensitive: A2 - Guideline cetuximab + adagrasib Sensitive : A2
KRAS G12C	Colon Cancer	KRAS G12C	Colon Cancer	cetuximab + adagrasib Sensitive: A2 - Guideline cetuximab + adagrasib Sensitive : A2	cetuximab + adagrasib Sensitive: A2 - Guideline cetuximab + adagrasib Sensitive : A2
KRAS G12C	Colon Cancer	KRAS G12C	Colon Cancer	panitumumab + adagrasib Sensitive: A2 - Guideline panitumumab + adagrasib Sensitive : A2	panitumumab + adagrasib Sensitive: A2 - Guideline panitumumab + adagrasib Sensitive : A2
KRAS G12C	Ampulla of Vater Carcinoma	KRAS G12C	Ampulla of Vater Carcinoma	adagrasib Sensitive: A2 - Guideline adagrasib Sensitive : A2	adagrasib Sensitive: A2 - Guideline adagrasib Sensitive : A2
KRAS G12C	Cholangiocarcinoma	KRAS G12C	Cholangiocarcinoma	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1
KRAS G12C	Ovarian Cancer	KRAS G12C	Ovarian Cancer	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1
KRAS G12C	Pancreatic Cancer	KRAS G12C	Pancreatic Cancer	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1
KRAS G12C	Endometrial Cancer	KRAS G12C	Endometrial Cancer	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1
KRAS G12C	Gastrointestinal Cancer	KRAS G12C	Gastrointestinal Cancer	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1
KRAS G12C	Pancreatic Ductal Adenocarcinoma	KRAS G12C	Pancreatic Ductal Adenocarcinoma	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1
KRAS G12C	Lung Cancer	KRAS G12C	Lung Cancer	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1
KRAS G12C	Solid Tumor	KRAS G12C	Solid Tumor	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1
KRAS G12C	Biliary Tract Cancer	KRAS G12C	Biliary Tract Cancer	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1	adagrasib Sensitive: C1 - Off-label adagrasib Sensitive : C1
KRAS G12C + STK11 mutation	Non Small Cell Lung Cancer	KRAS G12C + STK11 mutation	Non Small Cell Lung Cancer	adagrasib Sensitive: C3 – Early Trials adagrasib Sensitive : C3	adagrasib Sensitive: C3 – Early Trials adagrasib Sensitive : C3
KRAS G12C	Lung Adenocarcinoma	KRAS G12C	Lung Adenocarcinoma	adagrasib + TVB-3664 Sensitive: D – Preclinical adagrasib + TVB-3664 Sensitive : D	adagrasib + TVB-3664 Sensitive: D – Preclinical adagrasib + TVB-3664 Sensitive : D
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	sotorasib + adagrasib + VS-6766 Sensitive: D – Preclinical sotorasib + adagrasib + VS-6766 Sensitive : D	sotorasib + adagrasib + VS-6766 Sensitive: D – Preclinical sotorasib + adagrasib + VS-6766 Sensitive : D
KRAS G12C	Colorectal Cancer	KRAS G12C	Colorectal Cancer	sotorasib + adagrasib + VS-6766 Sensitive: D – Preclinical sotorasib + adagrasib + VS-6766 Sensitive : D	sotorasib + adagrasib + VS-6766 Sensitive: D – Preclinical sotorasib + adagrasib + VS-6766 Sensitive : D
KRAS G13D	Solid Tumor	KRAS G13D	Solid Tumor	adagrasib Sensitive: D – Preclinical adagrasib Sensitive : D	adagrasib Sensitive: D – Preclinical adagrasib Sensitive : D
KRAS Q99L	Solid Tumor	KRAS Q99L	Solid Tumor	adagrasib Resistant: D – Preclinical adagrasib Resistant : D	adagrasib Resistant: D – Preclinical adagrasib Resistant : D
KRAS A59T	Solid Tumor	KRAS A59T	Solid Tumor	adagrasib Sensitive: D – Preclinical adagrasib Sensitive : D	adagrasib Sensitive: D – Preclinical adagrasib Sensitive : D
KRAS A59S	Solid Tumor	KRAS A59S	Solid Tumor	adagrasib Sensitive: D – Preclinical adagrasib Sensitive : D	adagrasib Sensitive: D – Preclinical adagrasib Sensitive : D
KRAS R68M	Solid Tumor	KRAS R68M	Solid Tumor	adagrasib Sensitive: D – Preclinical adagrasib Sensitive : D	adagrasib Sensitive: D – Preclinical adagrasib Sensitive : D
KRAS Y96S	Solid Tumor	KRAS Y96S	Solid Tumor	adagrasib Resistant: D – Preclinical adagrasib Resistant : D	adagrasib Resistant: D – Preclinical adagrasib Resistant : D
KRAS Y96D	Solid Tumor	KRAS Y96D	Solid Tumor	adagrasib Resistant: D – Preclinical adagrasib Resistant : D	adagrasib Resistant: D – Preclinical adagrasib Resistant : D
KRAS G12C	Lung Cancer	KRAS G12C	Lung Cancer	adagrasib + ENV-201 Sensitive: D – Preclinical adagrasib + ENV-201 Sensitive : D	adagrasib + ENV-201 Sensitive: D – Preclinical adagrasib + ENV-201 Sensitive : D
KRAS G12C	Bladder Cancer	KRAS G12C	Bladder Cancer	adagrasib + nanoparticle albumin-bound rapamycin Sensitive: D – Preclinical adagrasib + nanoparticle albumin-bound rapamycin Sensitive : D	adagrasib + nanoparticle albumin-bound rapamycin Sensitive: D – Preclinical adagrasib + nanoparticle albumin-bound rapamycin Sensitive : D
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	adagrasib + nanoparticle albumin-bound rapamycin Sensitive: D – Preclinical adagrasib + nanoparticle albumin-bound rapamycin Sensitive : D	adagrasib + nanoparticle albumin-bound rapamycin Sensitive: D – Preclinical adagrasib + nanoparticle albumin-bound rapamycin Sensitive : D

Krazati (adagrasib)

Associations
(35)

Associations
(35)

Krazati (adagrasib)

Associations(35)

Associations(35)

Associations
(35)

Associations
(35)